27038-48-8

Usage

Uses

Used in Pharmaceutical Industry:
Furo[2,3-b]pyridin-3(2H)-one is used as a key intermediate in the synthesis of various pharmaceutical compounds for [application reason]. Its heterocyclic structure allows for the development of new drugs and pharmaceutical products with potential therapeutic benefits.
Used in Organic Synthesis:
Furo[2,3-b]pyridin-3(2H)-one is used as a versatile building block in organic synthesis for [application reason]. Its unique structure and properties enable the creation of a wide range of chemical compounds, facilitating further research and development in the field.

Upstream product

• 119293-17-3 3-Ethoxy-furo[2,3-b]pyridine-2-carboxylic acid 
• 40134-18-7 methyl 2-chloropyridine-3-carboxylate 
• 1279893-97-8 ethyl 3-oxo-2,3-dihydrofuro[2,3-b]pyridine-2-carboxylate 
• 2942-59-8 2-chloronicotinic acid 
• 851620-39-8 furo[2,3-b]pyridin-3(2H)-one hydrochloride 
• 1452-94-4 ethyl 2-chloronicotinate 
• 119293-09-3 ethyl 3-ethoxycarbonylmethoxyfuro<2,3-b>pyridine-2-carboxylate 
• 119293-13-9 ethyl 3-ethoxyfuro<2,3-b>pyridine-2-carboxylate 
• 109274-83-1 ethyl 3-hydroxyfuro<2,3-b>pyridine-2-carboxylate 
• 119292-93-2 3-ethoxyfuro<2,3-b>pyridine 
• 27038-46-6 3-(2-bromoacetyl)pyridin-2(1H)-one 

Downstream Products

• 1629241-51-5 4-(3-(3-methoxypropoxy)phenyl)-3,4-dihydropyrido[3',2':4,5]furo[3,2-d]pyrimidine-2(1H)-thione 
• 1620518-04-8 C₂₁H₁₆N₄O₂S 
• 1620518-03-7 R-4-(3-(3-methoxypropoxy)phenyl)-3,4-dihydropyrido[3',2':4,5]furo[3,2-d]pyrimidine-2(1H)-thione 
• 870061-94-2 2,3-dihydrofuro[2,3-b]pyridin-3-amine 
• 1421618-78-1 2-(2,4-dichloro-phenyl)-N-(2,3-dihydro-furo[2,3-b]pyridin-3-yl)-acetamide 
• 1421618-79-2 2-(2,4-dichloro-phenyl)-N-(2,3-dihydro-furo[2,3-b]pyridin-3-yl)-acetamide 
• 1421618-76-9 2-(2,4-Dichloro-phenyl)-N-(2,3-dihydro-furo[2,3-b]pyridin-3-yl)-acetamide 
• 109274-90-0 3-Methyl-furo[2,3-b]pyridine 
• 151384-57-5 2-[3-Hydroxy-3H-furo[2,3-b]pyridin-(2E)-ylidenemethyl]-benzoic acid methyl ester 

Relevant academic research and scientific papers

Hinge Binder Scaffold Hopping Identifies Potent Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2) Inhibitor Chemotypes

CAMKK2 is a serine/threonine kinase and an activator of AMPK whose dysregulation is linked with multiple diseases. Unfortunately, STO-609, the tool inhibitor commonly used to probe CAMKK2 signaling, has limitations. To identify promising scaffolds as starting points for the development of high-quality CAMKK2 chemical probes, we utilized a hinge-binding scaffold hopping strategy to design new CAMKK2 inhibitors. Starting from the potent but promiscuous disubstituted 7-azaindole GSK650934, a total of 32 compounds, composed of single-ring, 5,6-, and 6,6-fused heteroaromatic cores, were synthesized. The compound set was specifically designed to probe interactions with the kinase hinge-binding residues. Compared to GSK650394 and STO-609, 13 compounds displayed similar or better CAMKK2 inhibitory potency in vitro, while compounds 13g and 45 had improved selectivity for CAMKK2 across the kinome. Our systematic survey of hinge-binding chemotypes identified several potent and selective inhibitors of CAMKK2 to serve as starting points for medicinal chemistry programs.

GHRELIN O-ACYLTRANSFERASE INHIBITORS

This invention relates to novel compounds according to Formula (I) which are inhibitors of ghrelin O-acyltransferase (GOAT), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment

BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY

The present invention relatesto a pharmaceutical composition comprising acompound of the formula Ias described belowor a tautomeror a pharmaceutically acceptable salt thereof; to the compound of the formula Ias described below or a tautomer or a phar- mac

BENZOFURAN UREAS OR CARBAMATES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY

The present invention relates to benzofuran ureas or carbamates of formula I and heteroaromatic analogues thereof as described below or a tautomer or a pharmaceutically acceptable salt thereof; to a pharmaceutical composition containing these compounds, and to these compounds for use in therapy, especially for use in the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization. Formula (I) wherein X1 is CR1 or N; X2 is CR2 or N; X3 is CR3 or N; X4 is CR4 or N; with the proviso that at most two of X1, X2, X3 and X4 are N; E1 is O or NR6a; E2 is O or NR6b;with the proviso that E1 and E2 are not simultaneously O; L1 is a bond, optionally substituted C1-C6-alkylene or C3-C8-cycloalkylene; L2 is a bond, optionally substituted C1-C6-alkylene, C3-C8-cycloalkylene, etc.; A is 3-, 4-, 5-, 6-, 7- or 8-membered saturated, partially unsaturated or maximally unsaturated carbocyclic ring or a 3-, 4-, 5-, 6-, 7- or 8- membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring; or L2-A forms a group C1-C6-alkylene-OR13, C1-C6--alkylene-SR14 or C1-C6-alkylene-NR15R16; and R1, R2, R3, R4, R5, R6a, R6b, R13, R14, R15 and R16 are as defined in the claims and the description.

SPIROFUROPYRIDINE ARYL DERIVATIVES

Compounds of formula (I): and pharmaceutically-acceptable salts thereof, wherein: Ar is a moiety of formula (II) or (III): and A, B, and R1 are as defined in the specification, compositions containing such compounds and the use of such compounds and compositions for use in therapy.

FUROPYRIDINE DERIVATIVES

A class of substituted furo[2,3-b]pyridine derivatives are ligands for dopamine receptor subtypes within the body, in particular the D 4 subtype, and are therefore useful in the treatment and/or prevention of disorders of the dopamine system, in particula

Furopyridines. IX . Syntheses and Properties of 3-Ethoxy Derivatives of Furo-, Furo-, Furo- and Furopyridine

Reaction of ethyl 3-ethoxycarbonylmethoxyfuropyridine-2-carboxylates 2a-2d with sodium ethoxide afforded 3-ethoxy derivatives 3a-3d which converted to 3-ethoxyfuropyridines 5a-5d by hydrolysis and decarboxylation of the ester group.Vilsmeier reaction of 5a and 5b gave 2-formyl-3-ethoxy derivatives 6a and 6b and 2-formyl-3-chloro derivatives 7a and 7b, while 5c and 5d did not give any formyl compound.Bromination of 3-ethoxyfuropyridines with 1 equivalent mole of bromine gave 2-bromo-3-ethoxyfuropyridines 9a-9d, whereas reaction with 3 equivalents of bromine yielded 2,2- dibromo-3,3-diethoxy-2,3-dihydrofuropyridines (10a and 10b) and/or 2-bromo-3,3-diethoxy-2,3-dihydrofuropyridines 11b, 11c and 11d.Treatment of compounds 5a-5d with n-butyllithium in hexane-tetrahydrofuran at -70 deg C and subsequent addition of N,N-dimethylformamide yielded 2-formyl derivatives 6a-6d.

Furopyridines. VI. Preparation and Reactions of 2- and 3- Substituted Furopyridines

This paper describes the synthesis and chemical properties of some 2- and 3-substituted furopyridines.Reaction of ethyl 2-chloronicotinate 1 with sodium ethoxycarbonylmethoxide or 1-ethoxycarbonyl-1-ethoxide gave β-keto ester 2 or ketone 5, respectively.Ketonic hydrolysis of 2 afforded ketone 3, from which furopyridine 4 was obtained by the method Sliwa.While, 2-methyl derivative 7 was prepared from 5 by reduction, O-acetylation and the subsequent pyrolysis.Reaction of ketone 3 with methyllithium gave tertiary alcohol 8 which was O-acetylated and pyrolyzed to give 3-methyl derivative 9.Formylation of 4, via lithio intermediate, with DMF yielded 2-formyl derivative 10, from which 7, was obtained by Wolff-Kishner reduction.Dehydration of the oxime 11 of 10 gave 2-cyano derivative 12, which was hydrolyzed to give 2-carboxylic acid 13.Reaction of 3-bromo compound 14 with copper(I)cyanide gave 3-cyano derivative 15.Alkaline hydrolysis of 15 afforded compound 16 and 17, while acidic hydrolysis gave carboxamide 18.Reduction of 15 with DIBAL-H afforded 3-formyl derivative 19.Wolff-Kishner reduction of 19 gave no reduction product 9 but hydrazone 20.Reduction of tosylhydrazone 21 with sodium borohydride in methanol afforded 3-methoxymethylfuropyridine 22.